1. Home
  2. DAWN vs AHH Comparison

DAWN vs AHH Comparison

Compare DAWN & AHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • AHH
  • Stock Information
  • Founded
  • DAWN 2018
  • AHH 1979
  • Country
  • DAWN United States
  • AHH United States
  • Employees
  • DAWN N/A
  • AHH N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • AHH Real Estate
  • Sector
  • DAWN Health Care
  • AHH Finance
  • Exchange
  • DAWN Nasdaq
  • AHH Nasdaq
  • Market Cap
  • DAWN 624.8M
  • AHH 543.5M
  • IPO Year
  • DAWN 2021
  • AHH 2013
  • Fundamental
  • Price
  • DAWN $9.39
  • AHH $6.53
  • Analyst Decision
  • DAWN Strong Buy
  • AHH Buy
  • Analyst Count
  • DAWN 9
  • AHH 4
  • Target Price
  • DAWN $26.56
  • AHH $8.13
  • AVG Volume (30 Days)
  • DAWN 3.4M
  • AHH 940.1K
  • Earning Date
  • DAWN 11-04-2025
  • AHH 11-03-2025
  • Dividend Yield
  • DAWN N/A
  • AHH 12.69%
  • EPS Growth
  • DAWN N/A
  • AHH N/A
  • EPS
  • DAWN N/A
  • AHH 0.19
  • Revenue
  • DAWN $133,672,000.00
  • AHH $452,636,000.00
  • Revenue This Year
  • DAWN $12.88
  • AHH N/A
  • Revenue Next Year
  • DAWN $48.27
  • AHH $3.21
  • P/E Ratio
  • DAWN N/A
  • AHH $34.21
  • Revenue Growth
  • DAWN 31.11
  • AHH N/A
  • 52 Week Low
  • DAWN $5.64
  • AHH $6.01
  • 52 Week High
  • DAWN $14.46
  • AHH $11.24
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 60.96
  • AHH 53.22
  • Support Level
  • DAWN $8.16
  • AHH $6.01
  • Resistance Level
  • DAWN $9.77
  • AHH $6.30
  • Average True Range (ATR)
  • DAWN 0.70
  • AHH 0.18
  • MACD
  • DAWN -0.02
  • AHH 0.04
  • Stochastic Oscillator
  • DAWN 45.44
  • AHH 90.65

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

About AHH Armada Hoffler Properties Inc.

Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.

Share on Social Networks: